KaydedilenlerDerginizi ekleyin

Dergiler / Cyprus Journal of Medical Sciences / 2020 / Cilt: 5 - Sayı: 4

Exosome Mimetic Nanovesicles; Are They Next Best Alternative Therapeutic Approach Combating Cancer?

Cenk Serhan ÖZVEREL
Sayfa
361–364
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This review aims to summarize the current research studies on exosome mimetic nanovesicles together with their potential in combating cancer in the future.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Cancer is regarded as one of the most dangerous diseases despite the advances in technology and therapeutic strategies against it.
📊
Temel Bulgular & Veri:The current treatment strategies are ineffective as well as present with various disadvantages, such as drug resistances, ineffective uptake of the therapeutic agents at the tumor site, incompatible delivery of drugs, and immune-rejection, among others.
💡
Sonuç & Katkı:This review aims to summarize the current research studies on exosome mimetic nanovesicles together with their potential in combating cancer in the future.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Cancer is regarded as one of the most dangerous diseases despite the advances in technology and therapeutic strategies against it. The current treatment strategies are ineffective as well as present with various disadvantages, such as drug resistances, ineffective uptake of the therapeutic agents at the tumor site, incompatible delivery of drugs, and immune-rejection, among others. Extracellular vesicles, especially exosome mimetic nanovesicles, have become one of the latest focuses of research in anticancer therapies. The invention of these nano-sized vesicles, which function in cell-to-cell communication, have promoted the development of innovative drug delivery systems due to their cargo-carrying abilities and targeted deliveries. Exosome mimetic nanovesicles have similar surface protein structures to exosomes and offer various important advantages over the exosomes, such as the production yield and isolation protocol. This review aims to summarize the current research studies on exosome mimetic nanovesicles together with their potential in combating cancer in the future.

🔖

Bu Makaleye Atıf Yap

ÖZVEREL, C. S. (2020). Exosome Mimetic Nanovesicles; Are They Next Best Alternative Therapeutic Approach Combating Cancer?. Cyprus Journal of Medical Sciences, Cilt: 5 - Sayı: 4, 361–364. https://ajindex.com/articles/351126

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144(5): 646-74. [Crossref] 2. Michod D, Widmann C. DNA-Damage Sensitizers: Potential New Therapeutical Tools to Improve Chemotherapy. Crit Rev Oncol Hematol 2007; 63(2): 160-71. [Crossref] 3. Jackson SP, Bartek J. The DNA-Damage Response in Human Biology and Disease. Nature 2009; 461: 1071-8. [Crossref] 4. Schiff D, Wen PY, van den Bent MJ. Neurological Adverse Effects Caused by Cytotoxic and Targeted Therapies. Nat Rev Clin Oncol 2009; 6(10): 596-603. [Crossref] 5. Jacob A, Richard D J, O’Bryne KJ. EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. In: Mettinger K, Rameshwar P, Kumar V. (eds) Exosomes, Stem Cells and MicroRNA. Adv Exp Med Biol. 2018: 1056. 6. Crenshaw BJ, Sims B, Matthews QL. Biological Function of Exosomes as Diagnostic Markers and Therapeutic Delivery Vehicles in Carcinogenesis and Infectious Diseases. Nanomedicines; Intech Open Limited: London, UK, 2018. [Crossref] 7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review. J Control Release 2000; 65(1-2): 271-84. [Crossref] 8. Ferrari M. Nanogeometry: Beyond Drug Delivery. Nat Nanotechnol 2008; 3(3): 131-2. [Crossref] 9. Estanqueiro M, Amaral MH, Conceição J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces 2015; 126: 631-48. [Crossref] 10. Sajid M I, Jamshaid U, Jamshaid T, Zafar N, Fessi H, Elaissari A. Carbon nanotubes from synthesis to in vivo biomedical applications. Inter J Pharm 2016; 501(1-2): 278-99. [Crossref] 11. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the futurjkbjmnn e of chemotherapy. Eur J Pharm Biopharm 2015; 93: 52-79. [Crossref] 12. Zhu Y, Liao L. Applications of nanoparticles for anticancer drug delivery: a review. J Nanosci Nanotechnol 2015; 15(7): 4753-73. [Crossref] 13. Szebeni J, Storm G. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem Biophys Res Commun 2015; 468(3): 490-7. [Crossref] 14. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015; 93: 52-79. [Crossref] 15. Anderson HC. Vesicles associated with calcification in the matrix of epiphyseal cartilage. J Cell Biol 1969; 41(1): 59-72. [Crossref]